Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 487 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.00, for a total value of $10,714.00. Following the completion of the transaction, the insider directly owned 406,288 shares in the company, valued at approximately $8,938,336. This represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.00, for a total value of $95,000.00.
- On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00.
Adaptive Biotechnologies Stock Down 2.0%
ADPT traded down $0.42 during trading on Tuesday, hitting $21.08. The company’s stock had a trading volume of 42,487 shares, compared to its average volume of 2,258,578. The business’s 50 day simple moving average is $16.24 and its 200-day simple moving average is $15.90. The firm has a market cap of $3.37 billion, a PE ratio of -63.62 and a beta of 2.07. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $22.80.
Hedge Funds Weigh In On Adaptive Biotechnologies
A number of hedge funds have recently made changes to their positions in ADPT. 1492 Capital Management LLC bought a new position in shares of Adaptive Biotechnologies during the fourth quarter worth $1,484,000. Jupiter Asset Management Ltd. increased its holdings in Adaptive Biotechnologies by 33.8% in the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after acquiring an additional 91,683 shares during the last quarter. Rhenman & Partners Asset Management AB lifted its stake in Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after purchasing an additional 110,000 shares in the last quarter. UBS Group AG lifted its stake in Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock worth $8,314,000 after purchasing an additional 257,947 shares in the last quarter. Finally, Westfield Capital Management Co. LP bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Institutional investors own 99.17% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages have commented on ADPT. JPMorgan Chase & Co. reduced their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Morgan Stanley lowered their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Guggenheim boosted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. BTIG Research reissued a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Finally, TD Cowen raised their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.50.
Check Out Our Latest Stock Analysis on ADPT
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
- Five stocks we like better than Adaptive Biotechnologies
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
- Orbiting Capital: Lawmakers Buy SpaceX Ahead of Index Inclusion
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
- 3 Stocks With Solid Yields and Sustainabale Payouts Boost Dividends Once Again
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
